Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.

doi:10.1007/s00415-024-12608-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.

Journal of neurology - 1 Nov 2024

Clarelli Ferdinando, Corona Andrea, Pääkkönen Kimmo, Sorosina Melissa, Zollo Alen, Piehl Fredrik, Olsson Tomas, Stridh Pernilla, Jagodic Maja, Hemmer Bernhard, Gasperi Christiane, Harroud Adil, Shchetynsky Klementy, Mingione Alessandra, Mascia Elisabetta, Misra Kaalindi, Giordano Antonino, Mazzieri Maria Laura Terzi, Priori Alberto, Saarela Janna, Kockum Ingrid, Filippi Massimo, Esposito Federica, Boneschi Filippo Giovanni Martinelli

Abstract excerpt

BACKGROUND: Inter-individual differences in treatment response are marked in multiple sclerosis (MS). This is true for Natalizumab (NTZ), to which a subset of patients displays sub-optimal treatment response. We conducted a multi-centric genome-wide association study (GWAS), with additional pathway and network analysis to identify genetic predictors of response to NTZ. METHODS: MS patients from three different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germany

Share to Immunologic Factors

Share to Italy

Share to Multiple Sclerosis

Share to Pharmacogenetics

Share to Sweden

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39264442
DOI: 10.1007/s00415-024-12608-6
PMCID: PMC11561017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.PMID 39264442Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

Integrated multi-omics and machine learning prioritize key immune genes for multiple sclerosis risk prediction.Semantic proximity Read ↗

Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis.Semantic proximity Read ↗

A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches.Semantic proximity Read ↗

Prioritization of risk genes in multiple sclerosis by a refined Bayesian framework followed by tissue-specificity and cell type feature assessment.Semantic proximity Read ↗

Genetics and functional genomics of multiple sclerosis.Semantic proximity Read ↗

Summary-data-based mendelian randomisation reveals druggable targets for multiple sclerosisSemantic proximity Read ↗

Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis.Semantic proximity Read ↗

Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosisSemantic proximity Read ↗

IFN-beta pharmacogenomics in multiple sclerosis.Semantic proximity Read ↗

Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach.Semantic proximity Read ↗

Multi-omics integration prioritizes potential drug targets for multiple sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.